Search - tctmd.com

Displaying 221 - 240 of 272

Sort: Relevancy | Date

News Daily News

Deaths After Ablation of Atrial Fibrillation ‘Concerning’ in Real-World Analysis

Michael O'Riordan

October 29, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Conference News HFSA 2019

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

L.A. McKeown

September 23, 2019

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

L.A. McKeown

September 18, 2019

News Daily News

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

L.A. McKeown

September 13, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

Todd Neale

August 20, 2019

News Conference News HRS 2019

Cancer Survivors With Heart Failure Respond Well to CRT

Todd Neale

May 14, 2019

News Daily News

Digging In: Adherence to Plant-Based Diets Linked to Fewer HF Hospitalizations

L.A. McKeown

April 23, 2019

News Daily News

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

Michael O'Riordan

April 15, 2019

News Daily News

Stem Cell Research—Shattered After Fabrication Scandal—Needs to Rebuild, Says EHJ Editor

Michael O'Riordan

April 12, 2019

News Daily News

Survival Better With Early AVR for Severe Asymptomatic Aortic Stenosis, Says Retrospective Study

L.A. McKeown

March 29, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Conference News ACC 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Michael O'Riordan

March 25, 2019

News Conference News ACC 2019

Amlodipine the Key Component in Dual BP Therapy in Sub-Saharan Africa: CREOLE

Caitlin E. Cox

March 25, 2019

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Michael O'Riordan

November 11, 2018

News Features

Country Roads: Vulnerable West Virginia Heart Patients Targeted in Outreach Program

Michael O'Riordan

October 29, 2018

News Daily News

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

Todd Neale

October 02, 2018

Advertisement

Deaths After Ablation of Atrial Fibrillation ‘Concerning’ in Real-World Analysis

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

Cancer Survivors With Heart Failure Respond Well to CRT

Digging In: Adherence to Plant-Based Diets Linked to Fewer HF Hospitalizations

Most STEMI Patients Head to ICU After PCI, but Not All Need to Go

Stem Cell Research—Shattered After Fabrication Scandal—Needs to Rebuild, Says EHJ Editor

Survival Better With Early AVR for Severe Asymptomatic Aortic Stenosis, Says Retrospective Study

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Amlodipine the Key Component in Dual BP Therapy in Sub-Saharan Africa: CREOLE

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Country Roads: Vulnerable West Virginia Heart Patients Targeted in Outreach Program

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content